Browsing Tag
United States
1092 posts
Aramco’s green retreat: What the failed Repsol deal reveals about Big Oil’s future
Aramco paused a €1B bid for Repsol’s renewables unit. Learn why talks stalled, what it means for valuations, and how investors should respond.
How Celltrion’s $330m Eli Lilly deal positions it for a new era of U.S. biomanufacturing
Celltrion’s $330M purchase of Eli Lilly’s U.S. plant signals a tariff-proof pivot in biosimilars, reshaping pharma manufacturing in the U.S. today.
Boeing secures key Asia win as Vietjet receives first 737-8 from $32bn order
Vietjet’s first Boeing 737-8 delivery from its $32B order marks a fleet shift, investor focus on Boeing (NYSE: BA), and deeper US-Vietnam ties.
The environmental footprint of nuclear power: Balancing benefits and trade-offs
Compare nuclear’s carbon savings, land use, and safety with other energy sources—discover why it may be greener than you think.
Oklo becomes the hottest nuclear stock of 2025—should you buy, hold, or wait?
Discover how Oklo Inc (NASDAQ: OKLO) rocketed past expectations despite losses—what’s fueling the nuclear stock surge and whether investors should lean in now.
Will America’s new H-1B visa fee crush Indian IT’s global delivery model?
Find out how the new $100,000 H-1B visa fee could shake up Indian IT operations, disrupt projects, and reshape global talent flows.
Will Trump’s $100,000 H-1B visa fee end America’s reliance on foreign tech talent?
Trump’s new $100,000 H-1B visa fee could reshape U.S. immigration and global tech hiring. Explore its impact on Indian talent, employers, and innovation.
Tutors International joins forces with My Homeschool Expert to simplify elite homeschooling for UHNW families in the US
Discover how Tutors International and My Homeschool Expert are transforming UHNW homeschooling with bespoke tutors and 50-state legal compliance.
Nucor (NYSE: NUE) shares tumble after Q3 forecast disappoints the market
Nucor (NYSE: NUE) shares dropped after Q3 2025 guidance missed expectations. Explore why margins are under pressure and what it means for investors.
Why GSK is investing $30bn in the U.S. now—and what it means for global pharma manufacturing
GSK to invest $30B in U.S. R&D and manufacturing amid trade policy shifts—find out how this shapes global pharma supply chains and investor sentiment.